Viridian Therapeutics, Inc.\DE (VRDN) Company Report

Viridian Metals Inc. announced initial assay results from the first five holes of its 2025 drilling program at the Kraken Main Zone, confirming continuous, near-surface sulphide mineralization across 80 metres of strike.
The results included local high-grade copper zones such as 1.38% Cu (2.14% CuEq) over 0.7 metres from 4.45 metres depth, with several holes returning >20-metre mineralized intervals.
The company has now drill-tested the mineralized unit across 674 metres of strike, confirming continuity over more than 600 metres of trend.
Assays for an additional 360 metres of drilled strike at the Kraken Main Zone are currently pending, with results expected over the coming months.
Planning has begun for an expanded 2026 drilling program that will continue step-outs along the 5-kilometre anomaly and test newly identified structural splays.

Dec 10, 2025, 1:00 PM

Viridian Therapeutics Announces Q3 2025 Financial Results and Key Pipeline Progress

VRDN

Earnings

Debt Issuance

Product Launch

Viridian Therapeutics completed comprehensive financing transactions in October 2025, securing access to up to $889 million of potential capital, including $289.1 million gross proceeds from a public equity offering. This resulted in a cash position of approximately $887.9 million as of October 31, 2025, and the company believes it is funded through profitability.
The company successfully submitted a Biologics License Application (BLA) for veligrotug to the U.S. FDA in October 2025, with an anticipated U.S. commercial launch in mid-2026 if approved under Priority Review.
Topline data readouts for subcutaneous VRDN-003 in active and chronic Thyroid Eye Disease (TED) (REVEAL-1 and REVEAL-2) have been accelerated to Q1 2026 and Q2 2026, respectively, with a BLA submission planned for year-end 2026.
For the third quarter ended September 30, 2025, Viridian reported $70.6 million in total revenue, primarily from license revenue, and a net loss of $(34.6 million).

Nov 5, 2025, 12:09 PM

Viridian Therapeutics Submits BLA for Veligrotug in Thyroid Eye Disease

VRDN

Product Launch

New Projects/Investments

Viridian Therapeutics successfully submitted a Biologics License Application (BLA) to the U.S. FDA in late October for veligrotug, an investigational therapy for Thyroid Eye Disease (TED).
The BLA is supported by positive data from two pivotal phase 3 clinical trials, THRIVE and THRIVE-2, and veligrotug has been granted Breakthrough Therapy Designation, which supports eligibility for potential Priority Review.
An FDA decision on whether to accept the BLA for filing is expected within 60 days of submission, with a potential mid-2026 commercial launch if approved and granted Priority Review.

Nov 3, 2025, 12:01 PM

Viridian Therapeutics Prices Public Offering

VRDN

New Projects/Investments

Convertible Preferred Issuance

Viridian Therapeutics has priced an underwritten public offering of 11,425,000 shares of common stock at $22 per share, expected to raise approximately $251 million before expenses.
The proceeds from this offering will fund commercial launch activities for its thyroid eye disease (TED) treatments veligrotug and VRDN-003, research and development, working capital, and general corporate purposes.
The company also commenced an offering of Series B non-voting convertible preferred stock, which can be converted into common stock at a rate of 1 preferred share to 66.67 common shares.
Despite strong recent stock momentum and positive analyst sentiment, Viridian faces significant financial challenges, including operating losses with an operating margin of approximately -121,831% and a negative three-year revenue growth rate of -74.8%.